Bio + Health

The Next WebMD: An LLM as Your Front Door to Healthcare

Daisy Wolf and Julie Yoo Posted November 14, 2023

The internet and friends

You’ve most likely had an experience like this:

One day, you wake up with a hint of a headache and a sniffle. You sneeze. What do you do next? You Google it. You eventually land on WebMD. Was that sneeze a common cold or a bout of seasonal allergies? Or are you in fact dying from a rare form of nasal cancer? You determine you should see an allergist. But which one? How do you find a good one? Does your health plan require a referral? How much is this going to cost you? You text a friend who is a nurse, and another who works at the local hospital, hoping they’ll guide you in the right direction.

If so, you’re not alone. 1 billion health-related queries are submitted to Google every day, and 7% of overall questions asked to Google are health-related. WebMD is frequented by over 180 million people every month. It turns out that a broad set of the population turns to the internet and friends to figure out what their health condition might be, and which doctor to go see for it. In industry speak: the internet and your friend are today’s “front door to healthcare.”

A better way

While the Google –> WebMD –> Friend protocol may be a common way to enter into the healthcare system, it is certainly not an optimal one. Most of us are not well-equipped to self-diagnose from a list of possible conditions, and our friends who work in healthcare often don’t have the exact expertise we need. But when we turn to this protocol, what we’re effectively looking for is:

  1. Someone who knows enough to help us navigate to the right type of service (e.g. should we go to the urgent care clinic, or does this actually require a specialist?)
  2. Someone who knows the inside baseball of which specific doctor to see, and how to jump the scheduling line to get a timely appointment
  3. Someone who knows a little about how the insurance billing system works to prevent us from paying for something that we don’t have to

We’ve long imagined a version of the healthcare future in which every human has an all-knowing, empathic healthcare companion who fulfills these criteria based on personalized data—like a real life Baymax, the healthcare robot from the movie Big Hero 6.

But this isn’t entirely in the realm of fiction. The aforementioned tasks are what large language models (LLMs) are well poised to be tuned to do—e.g. exhibit college graduate-level smarts, follow some rules, send programmatic instructions to third-party software systems to take an action, and help provide empathetic, patient guidance to someone who is likely feeling stressed and confused due to uncertainty about a health issue.

Furthermore, they can escalate to a trained professional if they encounter a high-risk use case, or based on preference of the user. Hospitals and provider groups already hire hoards of their own call center agents to triage inbound consumers and make sure they are getting to the right site and type of care—because getting this wrong could mean wasting scarce appointment slots by sending the patient to the wrong type of doctor.

As such, we are optimistic about the opportunity for a specialist LLM to serve as a far more effective future front door to healthcare, integrating into a healthcare marketplace to enable people to book appointments and pay for their care.

From a patient perspective, the experience would also be much smoother:

One day, you wake up with a hint of a headache and a sniffle. You sneeze. What do you do next? You turn to your Baymax-like app, input your symptoms, and after a few follow up questions, it predicts— given your current location, the weather, your recent sleep scores, your diet, and your personal trends—that you’ve got allergies. It offers you a same-day appointment with a nearby allergist covered by your insurance to confirm the diagnosis. In the meantime, it recommends you try an over-the-counter allergy medication, offering to have it delivered to your house. It orders extra tissues for you, for good measure.

The size of the prize

Not only is this business a great opportunity to improve human health, patient experience, and provider experience, but the business case is also very clear.

First, the traditional businesses mentioned above are quite lucrative today. Health information sites like Google and WebMD make the majority of their revenue through ads; in 2016, the year before WebMD was taken private, it did $561 million in advertising revenue. The healthcare and pharmaceutical industry spends an estimated $18 billion a year on digital ads alone, usually advertising on condition-specific searches that indicate a consumer’s intent to engage with a specific healthcare product or service.

B2B revenue is also quite large for these businesses; WebMD offered “private portal” health information services products to health plans and employers that generated $114 million of revenue even back in 2016. Accolade, a comparable employer- and payor- sponsored navigation business, generated $300 million revenue in 2022.

Add to this the opportunity to monetize transactions once the LLM integrates into a marketplace of services that can be directly booked, and numerous revenue streams worth billions of dollars in aggregate become possible.

The next WebMD

While a big, white, puffy healthcare robot like Baymax is a possible manifestation of the future front door to healthcare, perhaps a more realistic one is an LLM tied to a healthcare services marketplace. We envision a not-so-distant future in which the daunting task of navigating the healthcare maze is significantly simplified for both patients and providers, with a viable business model to boot. When that happens, you’ll no longer need to self-diagnose, and your healthcare friends will thank you.

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.